Burns GC, Catala A, Paul S, Matute R, Onyema D, Toth I, Saha
DC
Response to early and prolonged inhibition of angiotensin
converting enzyme in HIV-associated nephropathy
Am Soc Nephrol
J Am Soc Nephrol (abstract)
(Nov) 6:414 1995
Three biopsy-proven patients with HIV-Associated nephropathy (HIVAN)
received fosinopril 10 mg daily and compared to 4 control patients.
Baseline characteristics were similar in the treated and control patients
(Serum creatinine 1.5 vs. 1.0, 24 hour protein 1.5 vs 0.7 grams). All
treated patients remained stable, while all control patients doubled their
creatinine within 6 months and became azotemic and nephrotic; differences
were statistically significant. By 12 months control patients required
dialysis. It was not clear how the control patients were selected, whether
they were biopsied and what other medications they received. Furthermore
this study did not appear to be randomized. Nevertheless, the conclusion
that ACEI's may prevent or delay the development of nephrotic syndrome and
progressive renal failure in selected patients with HIVAN is strongly
suggested, and further formal study warranted.
(Pastan)
To go back use the BACK button on your browser.
Otherwise click on the desired link to this article below:
Am Soc Nephrol
Proteinuria/Hematuria :
HIV-associated nephropathy